Updates are available Correction dated 2025-11-20
Click to view Correction: https://doi.org/10.1007/s40121-025-01266-4
-
Authors
Wilson, Michele https://orcid.org/0000-0003-4390-4192
Golan, Yoav
Nguyen, Dianne
Yazdani, Morteza https://orcid.org/0009-0004-0782-4472
Amin, Alpesh N. https://orcid.org/0000-0002-9790-0245
-
Funding
Funding for this research was provided by:
Nestlé Health Science
- License Information
-
More Information
Article History
Received: 10 December 2024
Accepted: 14 May 2025
First Online: 9 July 2025
Change Date: 20 November 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-025-01266-4
Declarations
:
: Michele Wilson is an employee of RTI Health Solutions, which received funding from Nestlé Health Science. Yoav Golan has served as principal investigator in clinical trials by Rebyota, Seres Therapeutics, and Vedanta, and has received honoraria from Nestlé and Rebyota. Dianne Nguyen and Morteza Yazdani are employees of Nestlé Health Science. Alpesh N. Amin served as principal investigator or co-investigator of clinical trials sponsored by Alexion, Blade Therapeutics, Eli Lilly, Fulcrum Therapeutics, Humanigen, NeuroRx Pharma, NIH/NIAID, Novartis, Octapharma, PTC Therapeutics, Pulmotect, and Takeda; and speaker and/or consultant for Alexion, AseptiScope, AstraZeneca, Bayer, Dexcom, Eli Lilly, Ferring Pharmaceuticals, Gilead, GSK, HeartRite, Novo Nordisk, Pfizer, Renibus Therapeutics, Reprieve, Salix, Seres Therapeutics, and Spero Therapeutics, outside the submitted work.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the author. As such, ethics review and approval was not required.
